Literature DB >> 1573039

An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of a clozapine rechallenge.

M G Goates, J I Escobar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1573039     DOI： 10.1097/00004714-199204000-00016

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  4 in total

1.  Rechallenging clozapine after neuroleptic malignant syndrome.

Authors:  Emaya Anbalagan; Muaid Ithman; John Lauriello
Journal:  Psychiatr Q       Date:  2014-09

Review 2.  When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature.

Authors:  Peter Manu; Deepak Sarpal; Owen Muir; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2011-11-22       Impact factor: 4.939

3.  Silent Neuroleptic Malignant Syndrome: A Case Report of Atypical Antipsychotic Induced Elevation of Creatinine Kinase and Altered Mental Status.

Authors:  Amber N Edinoff; Hamza Mohammad-Amin; Amira S Odisho
Journal:  Health Psychol Res       Date:  2022-08-20

Review 4.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.